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THE C-PHYCOCYANIN/BETA PROTEIN INHIBITS CANCER CELL PROLIFERATION
by
HAIZHEN WANG
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ABSTRACT
C-Phycocyanin (C-PC) from blue-green algae has been reported to have various
pharmacological characteristics, including anti-inflammatory and anti-cancer activities. In this
study, the β-subunit of C-PC (ref to as C-PC/β) was expressed and purified from bacteria E. coli
BL-21. The recombinant C-PC/β has been demonstrated to have anticancer properties. Under the
treatment of 5 µM of the recombinant C-PC/β, four different cancer cell lines accrued a high
proliferation inhibition and apoptotic induction. The C-PC/β interacts with membrane-associated
β-tubulin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been found. Under the
treatment of the C-PC/β, depolymerization of microtubulin and actin-filament was observed. The
cells underwent apoptosis with increase of Caspase-3 and Caspase-8 activities. Cell cycle was
arrested at G0/G1 phase under the treatment of C-PC/β. In addition, the nuclear level of GAPDH
decreased significantly. Inhibition of cancer cell proliferation and induction of apoptosis may
potentate C-PC/β as a promising cancer prevention or therapy agent.

Index Words: β subunit of C-Phycocyanin; Apoptosis; Cell cycle; Proliferation;
Caspase; β-tubulin; GAPDH
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INTRODUCTION

C-Phycocyanin (C-PC) and its biological functions
Blue-green algae or cyanobacteria belong to simple prokaryotes. They can be divided
into edible and inedible species. Edible blue-green algae are nutrient-dense, and they are rich in
proteins, vitamins, minerals, and essential fatty acids [Annapurna, 1991; Clement, 1975]. Studies
showed the effects of blue-green algae on immunity [Amar, 2004; Teneva, 2005], antiinflammatory response [Bruno, 2005], leukocyte trafficking [Mao, 2005], and processes antiviral effects [Schaeffer, 2000], as well as anti-cancer functions [Khan, 2005]. Previous studies
were based on the whole algae of various species treat to both human and animal studies,
including in vitro studies on algae extracts and purified compounds.
Phycobiliproteins are water-soluble fluorescent proteins derived from blue-green algae
and eukaryotic algae. In these organisms, they are used as accessory pigments for photosynthetic
light collection. The energy is absorbed by phycobiliprotein in the visible spectrum that are
poorly utilized by chlorophyll and, the energy is conveyed to chlorophyll at the photosynthetic
reaction center. Phycobiliproteins are classified into two large groups based on their color, the
phycoerythrins (red) and the phycocyanins (blue). The phycocyanins include C-Phycocyanin, RPhycocyanin, and allophycocyanin. C-Phycocyanin (C-PC) is the major phycobiliprotein in
many blue-green algae. The pigment has a single absorbance wavelength between 615 and 620
nm, and has a fluorescence emission at 640 nm. The molecular weight of this pigment is between
70,000 and 110,000 Da. Alpha and beta are the two subunits of the pigment. There are equal
numbers of alpha and beta subunits. However, the numbers of alpha-beta pair vary among the
different species. The intense blue color in blue-green algae is due to the phycocyanin.
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Phycocyanin serves as a protein storage unit and as an antioxidant [Benedetti, 2004]. C-PC is
widely used as natural dye for various purposes, due to its deep and intense color. C-PCs that
come from different species, such as Aphanizomenon sp. [Benedetti, 2006], Spirulina sp.
[Madhyastha, 2006], Phormidium sp.[Satyanarayana, 2005], Lyngbya sp.[Patel, 2005],
Synechocystis sp.[Rogner, 1990], Synechococcus sp.[Bryant, 1990], have been isolated and
studied.

Anti-cancer property of C-PC
The pharmacological effects of C-PC include hepatoprotection [Vadiraja, 1998],
antioxidation, anti-inflammatory [Romay, 1998], and radical scavenging [Bhat, 2001]. C-PC has
been shown to prevent the growth of malignancy cancer in vivo [Dainippon Ink & Chemicals,
1983]. In vitro experiment showed that C-PC have the capability of inhibition the growth of
cancer cells [Pardhasaradhi, 2003; Subhashini, 2004].
C-PC lowers the amount of cyclooxygenenase-2 which is usually upregulated in cancer
cells [Reddy, 2003]. It was shown that C-PC induces apoptosis by changing the Bcl-2/Bax ratio
(Bcl-2, anti-apoptosis protein; Bax, pro-apoptosis proteins; the ratio of Bcl-2/Bax represents the
degree of apoptosis) and the releases of cytochrome c into the cytosol. Phycocyanin induced
apoptosis in AK-5 cancer cells involves down-regulation of Bcl-2 [Pardhasaradhi, 2003].
Furthermore, when the leukemia cell line was treated with C-PC, the cleavage of poly (ADP)
ribose polymerase was enhanced [Subhashini, 2004]. Phycocyanin shows inhibitory effects on
cancer necrosis factor-alpha activity [Romay, 2001; Remirez, 2002]. C-PC induced Hela cell
apoptosis was caspase-dependent. Caspases-2, -3, -4, -6, -8, -9, and -10 are involved under C-PC
treatment [Li, 2006]. Percentage of cells arrested in sub-G0/G1 phase was increased under the
treatment with C-PC [Reddy, 2003; Subhashini, 2004; Li, 2006]. The activity of C-PC in the

2

induction of cancer cell apoptosis and its relatively low-toxicity of non-cancer cells make it a
very good candidate as a cancer prevention agent. However, the molecular mechanism
underlying the anti-cancer activities of C-PC is not well understood.
Apoptosis and cell cycle
Apoptosis, also called programmed cell death, is the mechanism complementary to
proliferation. When cells undergo apoptosis, several classical phenomena can occur, including
membrane blebbing, condensation of cytoplasm and the activation of endonuclease/ specific
proteases. Later on, the genome will be fractured, and smaller apoptotic bodies will be formed
[Bedner, 1999]. Macrophages will phagocytose the apoptotic cell. Through the process of
apoptosis, unwanted or dysfunctional cells can be eliminated. Two major apoptosis pathways
have been demonstrated. One is the mitochondrial/cytochrome C (intrinsic) pathway, which
activates Caspase-9 and Caspase-3. The second pathway is extrinsic pathway, in which extrinsic
signals activate Caspase-8 and Caspase-3. Caspase-3 is activated in most of the process of
apoptosis [Creagh, 2003]. Caspase-3 is the most important protein in the process of apoptosis.
Caspase-3 will finally induce the apoptotic morphologies, including DNA fragmentation and cell
shrinkage [Johnson, 2000].
The function of the cell cycle is to duplicate DNA and proteins and then separate the
copies into two daughter cells. The cell grows in interphase, which including S phase (DNA
replication), G1 phase (the gap between M phase and S phase), and G2 phase (the gap between S
phase and M phase). In M phase, the nucleus and the cytoplasm divide into two daughter cells.
Cell-cycle process can be arrested due to the intracellular or extracellular signals [von
Wangenheim, 1998].
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Tubulin and Glyseraldehyde-3-phosphate dehydrogenase (GAPDH)
Tubulin is the major protein component of microtubules. Microtuble system play
important roles in vesicle transport, chromosome segregation and maintain cell structure.
Tubulin is one of the intracellular molecular targets of many anticancer drugs [Hadfield, 2003;
Fojo, 2005]. Drugs like Taxel induce mitotic arrest and apoptosis in cancer cells through
disrupting the dynamics of tubulin [Loganzo, 2003].
GAPDH functions as a glycolytic enzyme within the cytoplasm [Tisdale, 2004]. GAPDH
also plays a role in other cellular processes including in membrane fusion [Han, 1998],
microtubule bundling [Sirover, 1999], phosphotransferase activity [Cooper, 1998], nuclear RNA
export [Kimura, 2000], DNA replication and DNA repair [Tatton, 2000]. It is also thought to be
involved in cell apoptosis [Tatton, 2000]. Abnormal expression [Tachibana, 2003], nuclear
accumulation [Senatorov, 2003], loss of enzymatic activity [Chuang, 2005], and changes in
physical properties of GAPDH were found to associated with several diseases [Chuang, 2005].
GAPDH was suggested to be a potential molecular target for drug development.

Purification methods and physical property of C-PC
To dates, all the previous studies used C-PC that was isolated from algae. The
purification involved a multi-step treatment of the crude extract, including fractional
precipitation with ammonium sulfate and separation over an ion-exchange chromatography
column [Patel, 2005] or a hydroxyapatite column [Benedetti, 2006], or a gel filtration
chromatography [Minkova, 2003].
Two components exist in many protein toxins: one component is responsible for the
enzymatic activity; the other component is utilized to translocate the enzymatic component into
the cells. The enzymatic activity component is released from the other component and exhibit
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toxicity. C-PC is a kind of toxin to cancer cells, though it is a non-toxic protein to normal cells.
The two subunits (α and β) form a heterodimer, which is very stable. Purified PC monomers can
form trimers, and two trimers can assemble into a hexamer [Saxena, 1988]. The pairs of α and β
subunits of C-phycocyanins have the same 3D structure; however, their sequence is different
[Glauser, 1992].
Specific Aims for this study
(i)

Determine whether the recombinant beta-subunit of C-phycocyanin has the anticancer properties (different cancer cell lines were used).

(ii)

Identify how the recombinant beta-subunit of C-phycocyanin inhibits the cancer cell
growth.

Choice of cell lines
In this study, six cell lines were used. Four of the cell lines are cancer cells, and two of
the cell lines are non-cancer cells. Respectively, 686LN was derived from a squamous cell
carcinoma of the head and neck patient’s metastatic tumor, 686LN-M4C1 was derived from
686LN cells passaged four times in nude mice; K562 is chronic myelogenous leukemia cells, and
HT 29 is colorectal adenocarcinoma; and two normal cell lines were used: C5/MJ is T
lymphocyte, RPMI 1788 is B lymphocyte. K562 was used to determine the appropriate dosage of
recombinant C-PC/β protein for the treatment. 686LN-M4C1 cell was used as the main study
system in order to figure out the anti-cancer mechanism of recombinant C-PC/β protein.
Overview of this study
In the present study, the recombinant C-PC/β protein was successfully obtained. The
optimum treatment dosage of the recombinant protein was determined based on the experimental
result using K562 cells (human chronic myeloid leukemia cells). The cell lines used in this study
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are: 686 LN (poorly metastatic parental head and neck cancer), 686LN-M4C1 (metastatic head
and neck cancer), HT 29 (Colorectal adenocarcinoma) and normal cell lines: C5/MJ (T
lymphocyte), RPMI 1788 (B lymphocyte). It is evident that the recombinant C-PC/β is an
inhibitor for cancer cell proliferation and an inducer for cancer cell apoptosis. The C-PC/β
inhibits cancer cell proliferation and promotes cancer cell apoptosis. The protein was the most
effective in 686 LN-M4C1 cells. Therefore this cell line was chosen to further study the
molecular mechanism of the effects. It showed that the protein depolymerized microtubule/
microfilament and affected GAPDH redistribution. The protein also arrested the cell cycle at
G0/G1 phase, and activated Caspases -3 and -8. This study demonstrated a new insight into the
molecular mechanism of anti-tumor activity of C-PC. More importantly, this study demonstrated
that the β subunit of C-PC has much higher anti-tumor activity, and the molecular mechanism of
anti-cancer appears different from that of the whole C-PC. On the other hand, both tubulin and
GAPDH are the targets by the C-PC/β. The recombinant C-PC/β protein shows potential in the
treatment of metastatic head and neck cancer.
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MATERIALS AND METHODS
Whole cell polymerase chain reaction (PCR) and plasmid construction
Blue-green algae or Cyanobacteria are Eubacteria. They have a rigid cell wall but no
mitochondria or other large organelles, and they have a single chromosome and the chromosome
exists as a linear or circular strand. Whole cell PCR is a method that can be used to obtain the
target DNA sequence without the need for purification of genomic DNA of the strain of interest.
This method is quite suitable to obtain the DNA sequence of Eubacteria, in that the unique
genomic DNA structure of the Eubacteria has no intron DNA sequences and the genomic DNA
is loosely packed. Nostoc PCC 7120 is one common strain of blue-green algae. Therefore, we
applied whole cell PCR to get the DNA fragments of β subunit of C-PC.
The published gene sequence of β subunit of C-PC was obtained from
www.Pubmed.com (Accession No. X05239). Living alga, Anabaena PCC 7120 was obtained
from the culture collection of algae at the University of Texas at Austin. The Anabaena pellet
was centrifuged and collected when the alga reached the exponential growth phase in BG11
medium. The alga was washed with distilled water, pelleted again in preparation for PCR.
Primers

used

to

amplify

the

GGGGATCCATGACATTAGACGTATTTA-3’

C-PC/β
and

reverse

were:

forward

5’-

5’-GGGAATTCTTTAA

CCAACAGCAGCAGCAG-3’. 50 µl of PCR mixture consists of: algae pellet 1 µl, forward
primer and reverse primer 0.3 µl each with the concentration (about 0.4 µg/µl), dNTP mixture
0.5 µl (10mM), Pfu DNA polymerase 1 µl, Pfu buffer 5 µl, and distilled water 41.9 µl. PCR
amplification was carried out for 35 cycles under denaturing –annealing –extension conditions of
94 ºC for 30 seconds, 55 ºC for 1 minute, 65 ºC for 4 minutes respectively.
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pGEX-2T is an expression vector for fusion proteins. It encodes a glutathione Stransferase gene at the N-terminal of the fused protein. A thrombin recognition site exists
between the GST and the fused protein. The pGEX vectors contain a tac promoter. The promoter
can be induced to express the recombinant protein with 1-5 mM IPTG. The expressed fusion
proteins will contain the 26 kDa glutathione S-transferase (GST). An ATG and ribosome-binding
site are included in the GST gene, which is under control of the tac promoter. A translation
terminator exists in each reading frame.
The PCR product of amplified DNA fragment coding the subunit of C-PC was obtained.
The product was cloned into SmaI-digested pGEM-4Z (cloning vector). Then the insert was subcloned into the BamHI and EcoRI sites of pGEX-2T, yielding plasmids pGEX-2T-β. The β
subunit of C-PC expressed from pGEX-2T-β consists of the β subunit fused at the C terminus to
a GST tag, in which includes a thrombin cleavage site. The constructed plasmid was verified via
DNA auto-sequencing.
Analysis of β subunit of C-PC based on the amino acid sequence
Transmembrane prediction and Protparam (Swiss-Prot/TrEMBL) soft analysis on the
website was performed to analyze the theoretical molecular weight, pI, hydropathicity,
transmembrane helices predicted, and stability level of the proteins (GST, GST:C-PC/β, and β).
The amino acid sequences of proteins were used. Based on the analysis results, we applied the
corresponding pH value when purifying or dialyzing the proteins we expressed.
Transformation of the constructed plasmid into the expression model E. coli BL-21
5 ml of LB medium with Ampicillin (100 mg/ml) was pre-warmed to 37ºC. Bacterial E.
coli BL-21 was thawed on ice. 100 µl of bacteria was aliquoted into 1.5 ml eppendorf tube. 100
ng of plasmid DNA was added to the tube, and the mixture was swirled softly and incubated on
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ice for 30 minutes. Then the tube was placed in the water bath at 42 ºC for 90 seconds (heat
shock). After that, the tube was placed on ice again for 2 minutes. Then 200 µl of pre-warmed
LB with Ampicillin was added to the tube and the tube was shaken (225 rpm) for 1 hour at 37 ºC.
Later on, 100 µl of the transformed E .coli was pipetted to pre-warmed LB agar plates
(Ampicillin was added), and spread with a bacterial spreader. The plates were incubated at 37 ºC
until the solution was absorbed, and were turn upside down and incubated overnight at 37 ºC.
The following morning, one single colony was picked up for culture and induction.
Expression and purification of the Recombinant β subunit of C-PC
GST-fusion proteins can bind to glutathione-Agarose. Therefore, a high degree of
purification of fusion protein can be achieved in just one affinity purification step. Tag-free
recombinant proteins can be obtained through removing the fusion tags by treatment with
enzymes. pGEX-2T allows for removal of the GST carrier protein from the fusion protein by
thrombin cleavage.
The constructed plasmids, pGEX-2T- β was transformed into E. coli BL-21 codonplus®,
and cultured in LB medium containing Ampicillin to A600nm=0.6. The expression of the
recombinant proteins was induced by 0.1 mM IPTG for 4.5 hours. 1 ml of culture solution was
collected and centrifuged, and the cell pellet was washed with PBS. The pellet was resuspended
in 100 ul 1×SDS-PAGE loading buffer, and heated to 95~100 ºC for 10 minutes. A 10% SDSPAGE gel was used to examine the expression of the protein. Additionally, cell pellets were
thawed and resuspended in lysis buffer (1% N-lauroyl sarcosine, 1 mM EDTA, 500 µM PMSF,
10 mM DTT in PBS, pH 7.3, pre-cooled to 4 ºC). The cell solution was sonicated for 3 minutes
and centrifuged at 15,000 rpm for 20 minutes. The supernatant was collected and filtered using a
0.45 µm syringe filter. The filtered supernatant was added to the glutathione-agarose and
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incubated at 4 ºC for 40 minutes with shaking. Then, a column was used to collect the beads and
the solution was filtered once more. The resin was washed with PBS-T (1% Triton X-100 and
1mM DTT) 4 times. GST- β was eluted and collected (10mM reduced glutathione in 50mM TrisHCl, pH 9.45) during this step. 40 units of thrombin were diluted into 3 ml PBS containing 1
mM DTT. The β subunit of C-PC were cleaved overnight using the protease solution. The beads
were washed and elution buffer was used to collect the GST protein.
HiLoad 16/60 Superdex 200 is used for gel filtration. Gel filtration is a liquid
chromatography technique that separates molecules according to their size. The selectivity curve
is usually fairly straight over the range Kav=0.1 to Kav=0.7, which shows in Graph 1. The
molecular weight range, which lies between these values, is defined as the useful fractionation
range of the medium.
According to Graph 1, the proteins with a molecular weight between 30,000 Da–600,000
Da MW are high on the selectivity range for Superdex 200 prep grade. The molecular weight of
GST-β and β are within this range, therefore, we used Sephedex 200 gel-filtration column to
further purify the proteins (GST tagged β subunit of C-PC and GST).
Centriprep Centrifugal Filter Devices were applied to concentrate the GST tagged β
subunit of C-PC and GST recombinant proteins (3×1000g, 4 ºC).
Refolding and dialysis of the protein β and GST-β
One liter of PBS (pH 7.3, pre-cooled to 4 ºC) was prepared, which is over 50 times of the
volume of the sample. DTT was added to a final concentration 0.1 mM. The protein sample was
dialyzed for at least 3 hours at 4 ºC. The buffer was changed (same components) and the sample
was dialyzed for an additional 3 hours. Finally, the protein sample was dialyzed through two
additional round with buffer without DTT. A dialysis buffer containing 1mM reduced
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glutathione and 0.2mM oxidized glutathione in 1× PBS (over 25 times volume of sample) was
prepared and chilled to 4 ºC. The refolded protein was dialyzed overnight at 4 ºC (if disulfide
oxidation or isomerization required, continued with this step). Then the protein sample was
dialyzed for another 3 hours in PBS only and the protein activity was assayed.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE is the most commonly used protein electrophoresis method. First, SDS and a
reducing agent such as DTT are added on a weight ratio basis: 1.4 mg SDS per 1 g protein, and
temperature is elevated to over 100 ºC to denature the proteins. The denatured proteins are
wrapped with SDS molecules. The proteins are mainly separated according to sizes of proteins
regardless of the charges. Theoretically, SDS-PAGE can separate proteins from around 10,000
Da to 300,000 Da molecular weights by varying pore sizes of the gels. The pore size of the gel
can be varied by adjusting the ratio of the acrylamide, cross-linker, and bisacrylamide. SDSPAGE can be used for assessing purity and as a tool to primarily determine the molecular
weights by comparing the unknown sample with the known protein. To separate the protein
bands, silver- or Coomassie Blue-staining methods can to be used to visualize the proteins. In
this experiment, 10% or 14% gels were used to show the expression level, the molecular weight,
and the purity of the proteins.
Protein Mass Spectrometry.
Because the protein samples in SDS-PAGE are denatured, its application in detecting
conformational change is limited. Here, we further use the protein mass spectrometry to show
the molecular weight and the purity level of the proteins.
The samples were dialyzed into 10 mM Tris-HCl buffer with the same pH value of 7.3,
concentrated by vacuum centrifugation, and subsequently applied to ZipTip C18 tips for
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desalting and concentrating. After ZipTip purification, the proteins were eluted from the ZipTip
with a Cyano-4-Hydroxycinnamic acid (CHCA) solution in 50% acetonitrile (CAN)/ 0.1%
formic acid and spotted directly onto a wax-coated matrix-assisted laser desorption/ionization
target plate. Protein mass spectrometry analysis was applied to the samples.
Cell culture and protein treatment
Cell proliferation was determined using the MTT assay. Human chronic myeloid
leukemia K562 cells (2×104/ well, 96-well plate) with fresh RPMI 1640 medium (10% FCS)
were first treated with 0.44 µM and 4.4 µM recombinant β subunit of C-PC (PBS buffered, pH
7.3), and PBS buffer treatment was used as a control. 686LN-M4C1, 686LN, K562, HT 29,
C5/MJ and RPMI 1788 cells were seeded on plate (2×104/ well, 96-well plate) with appropriate
fresh media. Adherent cells were seeded for 24 hours, the medium was then changed on the
second day prior to treatment. The suspension cells were inoculated on the same day. 5 µM of
the recombinant β subunit of C-PC protein was used to treat the different cell lines. All the
proteins added were PBS buffered (pH 7.3). 5 µM of GST and PBS were used as two controls.
Morphological changes were examined using light microscopy (100×) daily, for three days.
Cultures were maintained in a humidified atmosphere with 5% CO2 at 37

for 48 hours.

MTT assay method
In this experiment we use CellTiter 96® non-Radioactive Cell Proliferation Assay to
assay the activity of the C-PC/β on the different cell lines.
In our experiment, after treatment, an MTT assay: CellTiter 96® non-Radioactive Cell
Proliferation Assay was performed. 15 µl of the Dye Solution was added to each well. The plate
was incubated at 37°C for up to 4 hours in a humidified, 5% CO2 atmosphere. After incubation,
100 µl of the Solubilization/Stop Solution was added to each well. One hour after addition of the
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Solubilization/Stop Solution, the contents of the wells were mixed to obtain a uniformly colored
solution. The absorbance values at 570 nm were determined on a multi-well plate reader. The
assay was performed on samples and controls in triplicate.
Apoptosis detection of protein treated cancer cells (Cell Death Detection ELISAPLUS)
686LN-M4C1, 686LN, K562 and HT 29 cells were seeded (2×105/ well, 12-well plate)
with corresponding fresh medium. The same concentration of the recombinant β subunit of C-PC
protein (5 µM) was applied to all cell lines. 5 µM of GST and PBS treatment were used as two
controls. On the third day, the same amount of treated and untreated cells (5×104 cells) per the
Cell Death Detection ELISAPLUS were counted and collected. The cells were washed with precooled PBS, centrifuged and resuspended in 200µL of lysis buffer. The cells were lysed for 30
minutes at room temperature, centrifuged at 200 g for 10 minutes. 20 µL of supernatant solution
from each control was transferred to Streptavidin-coated microplates and shaken for 2 hours at
room temperature. The solution was removed and rinsed with incubation buffer. 100 µL substrate
solution was added and incubated until the color development was sufficient for a photometric
analysis at 405 nm using the substrate solution as a control blank. The specific enrichment of
mono- and oligonucleosomes released into the cytoplasm was calculated from these values using
the following formula: enrichment factor= absorbance of the sample (treated) / absorbance of the
corresponding negative control (non-treated).
Caspases activation detection
Caspases exist in inactive form and active form. Only when the regulatory domain is
cleaved, Caspases an be activated. The status of caspases can be detected via immunoblots
method with specific antibodies. 686LN-M4C1 cells were inoculated into 6-well dishes with
corresponding fresh medium. The same concentration of the recombinant β subunit of C-PC
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protein (5 µM) was added to the cells, PBS treatment was used as a control. Cells were collected
24 hours after addition of the protein. 1×RIPA buffer supplemented with protease inhibitors was
used to prepare whole cell lysates. 50 µg of the protein was used for the immunoblotting. A 14%
SDS-PAGE gel was utilized to separate the proteins. The immunoblots were probed with
appropriate antibodies: mouse monoclonal antibodies of anti-Caspase-3, anti-Caspase-8 and
rabbit monoclonal antibody of anti-cleaved-Caspase-3.
Fluorescence Activated Cell Sorting (FACS) analysis of cell cycle
686LN-M4C1 cells were inoculated into 6-well dishes with corresponding fresh medium.
The same concentration of the recombinant β subunit of C-PC protein (5 µM) was added to the
cells, PBS treatment was used as a control. After the above treatment (48 hours), 1~2×106 cells
were harvested and washed in PBS, then fixed with 1% (w/v) paraformaldehyde (methanol free)
and placed on ice for 15 minutes. After the cells were washed with pre-cooled PBS, they were
resuspend in 5 ml of ice-cold 70% (v/v) ethanol. The cells stood for 30 min on ice or cell
solution was stored in the freezer (-20 ) until the next step. Cells were stained with 0.5 ml
PI/RNase staining buffer (51-6585AZ, BD Bioscience) for 15 minutes at 37ºC and analyzed by
FACS (Becton Dickinson) (FL2-A).
Immunofluorescent confocal microscopy
686LN-M4C1, 686LN, K562, and HT 29 cells were seeded into culture wells (4×104/
well, culturewellTM chambered cover-glass for cell culture) with corresponding fresh media. 5
µM of the recombinant β subunit of C-PC protein was added to the cells. On the third day, a
general fixation protocol was used to prepare the samples as follows: the cells were rinsed with
pre-warmed buffer and fixed with 3.7% formaldehyde; the cells were rinsed and permeabilized
in 0.1% Triton X-100; the cells were blocked with Image-iTTM FX signal enhancer; the samples
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were incubated with the GST antibody in 1:50 dilution; the cells were washed and incubated
with second detection conjugates (Alexa Fluor 488 goat anti-mouse IgG (H+L) in 1: 200 dilution;
the samples were mounted with Prolong Gold anti-fade reagent, and allowed to cure until ready
to examine via laser scanning confocal microscope (Zeiss LSM 510). The above method was
applied to the adherent cells; however, for suspension cells, centrifugation at 1,000 g at 4 degree
Celsius for 10 minutes was used to replace the medium, buffer and reagents.

Membrane protein extraction
Mem-PER® Eukaryotic Membrane Protein Extraction Reagent Kit was used to obtain
the membrane protein extracts. 5 x 106 cells were obtained by centrifuging harvested 686LNM4C1cell suspensions at 850 × g for 2 minutes. Cells were washed by PBS and were pelleted in
1.7 ml microcentrifuge tubes. The supernatant was carefully removed and discarded. 150 µl of
Reagent A was added to the cell pellet. A homogeneous cell suspension was obtained by
pipetting up and down. The suspension was incubated 10 minutes at room temperature with
occasional vortexing. The lysed cells were placed on ice. One part Reagent B was diluted with
two parts Reagent C. Reagents B and C were kept at 4°C or on ice at all times. 450 µl of diluted
Reagent C was added to each tube of lysed cells and vortexed. The tubes were incubated on ice
for 30 minutes, vortexing every 5 minutes. The tubes were then centrifuged at 10,000 × g for 3
minutes at 4°C. The supernatant was transferred to new tubes and incubated for 10 minutes at
37°C to separate the membrane protein fraction. The tubes were centrifuged at room temperature
for 2 minutes at 10,000 × g to isolate the hydrophobic fraction from the hydrophilic fraction. The
hydrophilic phase (top layer) was carefully removed from the hydrophobic protein phase (bottom
layer) and saved in a new tube. The separated fractions were placed on ice. The majority of
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membrane proteins should be in the lower hydrophobic fraction, which was used for membrane
protein analysis.
The detergent in the membrane fraction was reduced through dialysis so that the sample
was compatible with the pull-down experiment. The sample was dialyzed overnight at 4ºC
against a buffer that contains 0.5% detergent (NP-40) to maintain protein solubility as buffer
exchange occurs. A volume that was 150-fold greater than the volume of the sample was used to
dialyze and the dialysis buffer was changed twice.
Pull-down assay
The GST tagged C-PC/β was pre-bound to the glutathione-agarose beads. The GST
moiety and the column were used as controls. The beads were incubated with the membrane
protein extracts prepared as above. The agarose beads were washed 5 times with PBS buffer
containing 0.5% NP-40. The GST pull-down proteins were separated by SDS-PAGE. The gels
were stained with the gelcode® blue stain reagent (Pierce).
Associated protein identification (TOF/TOF-MS)
The identified protein bands (pulled-down by the C-PC/β) were sliced out and placed in
siliconized eppendorf tubes. The gel piece was covered with 200 µl of Destaining Solution and
incubated at 37 °C for 30 minutes. The solution was removed and discarded from the tube
(repeated 2 times). The gel piece was dried in a speed vacuum for approximately 30 minutes. 20
µl (0.4 µg of trypsin) of the prepared Trypsin Solution was added to the gel sample. 50 µl of the
Trypsin Reaction Buffer was added to the gel sample and the sample was incubated for 4 hours
at 37 °C. After the incubation, the liquid was removed from the gel piece and the liquid was
transferred to a new tube. This solution contained the extracted tryptic peptides, which were
ready for TOF/TOF-MS analysis. The mass spectrometer first obtained MS spectra of each of the
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samples followed by MS/MS analysis of the 25 most abundant peptide peaks from each spectrum.
The combined MS and MS/MS data was used to search the NCBI database. Peptides with “ion
scores” were fragmented by MS/MS and ion scores above 30 were considered significant.
Coimmunoprecipitation (Co-IP) to further prove the interaction of the protein
The GST tagged C-PC/β was pre-bound to the glutathione-agarose beads. The GST
moiety and the column were used as controls. The beads were incubated with the membrane
protein extracts prepared as above. The agarose beads were washed 5 times with PBS buffer
containing 0.5% NP-40. The GST pull-down proteins were separated by SDS-PAGE. The pulldown proteins were further analyzed by immunoblot using antibodies against β-tubulin and
GAPDH.
30µL of Immunopure Protein A agarose (capture reagent) which was equilibrated to 50%
in the appropriate wash buffer (equilibration: 3 washes with wash buffer for IP) was prepared.
The first antibodies (polyclonal antibody against GAPDH or polyclonal antibody against βtubulin) and capture agent were pre-coupled separately (The mixture were incubated for 2 hours
at 4 ºC, and washed by PBS buffer containing 0.5% NP-40 for three times). The pre-coupled
agarose was centrifuged and then incubated with the membrane protein extracts for 4 hours at 4
ºC. The beads and associated proteins were centrifuged and washed for 5 times. Loading buffer
was added to the beads, and followed by vortexing, boiling, and running SDS-PAGE gels. The
interactions of C-PC/β with β-tubulin and GAPDH were shown by co-immunoprecipitates,
which followed by immunoblot using antibodies against β-tubulin, GST and GAPDH,
respectively.
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Nuclear and cytoplasmic protein extracts
Cells were gently removed from dish by scraping with cell lifter. Cells were washed with
ice-cold PBS with phosphatase inhibitors and the cell suspension was centrifuged for 5 minutes
at 500 rpm in a centrifuge pre-cooled at 4ºC. This step was repeated three times. The supernatant
was discarded and the cell pellet was placed on ice. The cell pellet was gently resuspended in
500 µL 1X Hypotonic Buffer by pipetting up and down several times. The suspension solution
was transferred to a pre-chilled microcentrifuge tube and was incubated for 15 minutes on ice. 25
µl of detergent was added and the sample was vortexed for 10 seconds at the highest setting. The
suspension solution was centrifuged for 30 seconds at 14,000 x g in a microcentrifuge pre-cooled
at 4ºC. The supernatant (cytoplasmic fraction) was transferred into a pre-chilled microcentrifuge
tube and stored at –80ºC until ready to use. The nuclear pellet was resuspended in 50 µL
Complete Lysis Buffer by pipetting up and down. The sample was vortexed for 10 seconds at the
highest setting. The suspension solution was incubated for 30 minutes on ice on a rocking
platform set at 150 rpm. Then the sample was vortexed for 30 seconds at the highest setting. The
sample was centrifuged for 10 minutes at 14,000 x g in a microcentrifuge pre-cooled at 4ºC. The
supernatant (nuclear fraction) was transferred into a pre-chilled microcentrifuge tube and stored
at –80ºC.
Soluble and assembled tubulin / actin measurement
Soluble (depolymerized) tubulin / actin and assembled (polymerized) tubulin /actin were
measured as described previously [Ogawa, 2002]. Briefly, 686LN-M4C1 cells were treated with
PBS or the recombinant β subunit protein for one day. After treatment, cells were washed with
PBS containing 0.5 µg/ml Paclitaxel, and lysed with 100 µL of lysis buffer (20mM Tris-HCl,
0.5% NP-40, 1mM MgCl2, 2mM EGTA, and 0.5 µg/ml Paclitaxel). Then the samples were
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vortexed and centrifuged at 12,000×g for 10 min at 4ºC. Supernatants containing soluble tubulin
/ actin were separated from pellets containing polymerized tubulin /actin and placed in separate
tubes. 100µl of water was used to wash the pellets. Lysis buffer was used to dissolve the pellets.
A 14% SDS-PAGE gel was utilized to separate the proteins and immunoblots were probed with
appropriate antibodies (antibody of β-tubulin, antibody of actin). The band of each sample was
quantified through the use of an imaging program (Biochemi System), and the ratios of
depolymerized to polymerized tubulin/actin were calculated for each treatment condition.
Expression level and subcellular distribution of GAPDH
The western blot technique was used to detect the distribution of the GAPDH. 686LNM4C1 cells were seeded into 6-well dishes with corresponding fresh medium. The same
concentration of the β subunit of C-PC protein (5 µM) was applied to the cells, and PBS
treatment was used as the control. Cells were collected 24 hours after the addition of the protein.
The cells were washed with pre-cooled PBS and a Nuclear Extraction kit was used to isolate the
nuclear located proteins (The detailed steps were described previously). 115 µg of the nuclear
proteins was used for immunoblotting to detect the distribution of the GAPDH. Meanwhile, 50
µg of the whole cell lysate proteins was used to detect the expression level of GAPDH under
treatment. A 14% SDS-PAGE gel was utilized to separate the proteins and immunoblots were
probed with appropriate antibodies: mouse monoclonal antibodies of anti-GAPDH.
Tubulin is one of the housekeeping genes. From the primary result, it showed that the
expression level of tubulin did not changed significantly. Therefore, we used tubulin as our
loading control. Histone 2A, exists inside of the nucleus. Here we used it as a control to show
that there was no contaminantion of cytoplasmic extracts from nucleus.
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50 µg of the cytoplasm proteins and nuclear proteins were used for the immunoblots of βtubulin and Histone H2A. Monoclonal antibody against β-tubulin and polyclonal antibody
against Histone H2A were used.
Statistical analysis
The results were expressed as mean ± S.D. of data obtained from three independent
experiments. Statistical analysis of difference was carried out by analysis of variance (ANOVA).
The level of significance was set at P<0.05. (The analysis method was same used in the
following experiment.)
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RESULTS
Whole cell PCR product and plasmid were obtained
Whole cell PCR is quite suitable to clone the C-PC DNA sequence from Nostoc PCC
7120 (Figure 1). PCR products also were blunt ligated into the Smal I digested pGEM-4Z
(Figure 2a), and sub-cloned into pGEX-2T (Figure 2b). We single-enzyme-digested the vectors,
used the corresponding empty vector as a control, and compared the molecular size to test
whether the vector has been cloned with the DNA sequence. We succeeded in obtaining the
vector containing the DNA sequence. The constructed plasmid was sent for sequencing.
Theoretical analysis results of corresponding proteins
Amino acid sequences of subunits of C-PC and GST are available from the PubMed, or
we can decode the corresponding DNA sequences into the amino acid sequence (Table 2.1).
Through Modern Transmembrane Prediction and Protparam (Swiss-Prot/TrEMBL) soft analysis,
we found that the theoretical molecular weight of GST is around 28165.7 Da, GST-β is around
46678.6 Da (Table 2.2). All the proteins were determined to be stable. β subunit of C-PC shows
higher hydropathicity and no transmembrane helices were predicted. It shows that the theoretical
pI of β is 5.00. At the same time, the grand average of hydropathicity (GRAVY) is -0.025 (β).
The estimated half-life of two subunits is around 30 hours applied to mammalian cells in vitro.
According to the pI of the proteins and our study purpose, we decided to use PBS with the pH
7.2 ~ 7.4 to purify and dialyze all the proteins.
High level expression and high purity of recombinant subunits of C-PC
The DNA fragments were cloned into the expression vector pGEX-2T and the subunits of
C-PC were subsequently expressed in E. coli BL-21 as GST-fusion proteins. High expression
level of C-PC/β was observed (Figure 3). After purification over a glutathione-agarose beads
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column and a sephedex 200 gel-filtration column, high purity and concentration of the
recombinant proteins were obtained (Figure 4). The concentration of the C-PC/β protein was
estimated to be 0.9 mg/ml.
Effective refolding and dialysis of the recombinant proteins
Since the β subunit contained three Cysteine amino acids, the protein can form disulfide
bonds with itself through refolding and dialysis. Two bands on the SDS-PAGE gel were obtained
when the refolded protein sample was treated by the loading buffer without reducing reagent
(Figure 5, lane 1). While only one band on the SDS-PAGE gel was observed when the protein
sample was treated with the loading buffer containing the reduce reagent (Figure 5, lane 2). The
band which runs faster is reasoned to be the protein formed the disulfide bond, while the other
one is linear protein (Figure 5, lane 1). In the following experiment, we used the proteins that
were refolded and dialyzed and which showed highly toxic activity to cancer cells.
MS results were consistent with the theoretical molecular weights of the proteins
Molecular weights of obtained recombinant proteins were determined by MALDI-TOF
mass spectrometry (Figure 6). The mass spectrometry results indicated that the obtained GST:CPC/β had MW 45.4 kDa and the GST had MW 27.1 kDa respectively. These molecular weights
were consistent with the corresponding calculated MWs. The results also reflected that the
proteins we got were in high level of purity.
The C-PC/β inhibits cell proliferation
C-PC was reported to inhibit cell proliferation in a number of cancer cell lines
[Pardhasaradhi, 2003; Subhashini, 2004]. We first determined the appropriate dosages of C-PC/β
on human chronic myeloid leukemia cell line, K562. The proliferation rates of cells under the
treatment of 0.44 uM and 4.4 uM of C-PC/β were around 98% and 60.8%, respectively (PBS
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treatment was set as 100%) (Figure 7). Based on this results, we dertermined the optimum dose
of the protein to the K562 cell was around 5 µM. We applied this concentration of the protein to
study the pharmacological effecfts in the following experiment. To test whether the recombinant
C-PC/β also has the ability to inhibit the growth of different cancer cells, we carried out the MTT
assay with a number of cancer cell lines and two normal cell lines: 686LN, 686LN-M4C1, K562,
HT 29, C5/MJ and RPMI 1788. The same concentration of GST protein and PBS were used as
controls. Growth of all cancer cells was largely inhibited by treatment with C-PC/β. The greatest
inhibitory effect on the cell proliferation occurred to 686LN-M4C1 cells, which the growth
proliferation of the cells was 39.6% (PBS treatment was used as a control). On the other hand,
the C-PC/β had a minor inhibitory effect on growth of non-cancer cells (inhibitory ratios of
C5/MJ and RPMI 1788 cells were 29.7% and 25.2% respectively, Figure 8). As a control, GST
alone had no significant effects on the growth of any of the cell lines tested.
The morphology of cells can be important in many contexts. In culture, the morphology
indicates the health status of the cells. We observed the morphologies of the different cells were
changed greatly under the treatment of C-PC/β. We noticed that the morphology of cancer cells
changed when the cells were treated with the C-PC/β. 686LN-M4C1 cells became nontransparent and distorted (Figure 9). Other cancer cell lines also changed significantly upon the
treatment with C-PC/β. A majority of K562 cells changed from a round to a spindle-like
morphology. HT29 cells grew sparsely. The 686LN cells became clustered and distorted. In
contrast, no significant changes in morphology of non-cancer cells were observed under the same
treatments.
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Recombinant C-PC/β induced cancer cell apoptosis
We speculated that the observed cell growth inhibition and cell morphology changes
were due to induction of apoptosis by the C-PC/β treatment. To test the speculation, we
examined apoptosis with all cancer and non-cancer cells using a commercially available
apoptosis kit. Our experiments demonstrated that apoptosis was induced in three cancer cells
upon the C-PC/β treatments. Highest level of apoptotic induction was observed with the
metastatic head and neck cancer cells, 686LN-M4C1 (The enrichment factor of mono- and
oligonucleosomes was approximately 4.0). As a control, GST alone did not induce apoptosis in
any of the cells tested (Figure 10). No clear apoptosis was observed with non-cancer cells under
the treatment of C-PC/β.
Activation of caspases are often associated with cell apoptosis [Landry, 2006]. The
metastatic head and neck cancer cells 686LN-M4C1 suffered the highest degree of growth
inhibition and apoptosis, we chose this cell line as our test system for probing caspase activity.
Under the treatment of the C-PC/β, both Caspases -8 and -3 were activated as revealed by the
cleavage of pre-Caspase-8 and pre-Caspase-3 (Figure 11). These results may suggest that the CPC/β triggered 686LN-M4C1 cell apoptosis by activation of the extrinsic cell death pathway.
Cells were arrested in G0/G1 phase
The cell cycle profiles were monitored 48 hours after C-PC/β treatment. An accumulation
of cells with 2 N DNA content and a decrease in cells with 4 N DNA were evident by comparing
to that of untreated cells (Figure 12). This result indicated that 686LN-M4C1 cells were mainly
in the G0/G1 phase after the cells were treated with the C-PC/β. In addition, an increase in the
number of cells with a sub-G1 DNA contents was clearly observed, which is a typical
characteristic of cells under apoptosis (Figure 12). DNA fragmentation was produced during the
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apoptosis process and some of them were eluted after the fixing and washing steps [Peng, 2005].
This observation provides an additional support for our conclusion that C-PC/β treatment
induces apoptosis and cell cycle arrest.
Recombinant C-PC/β accumulated on plasma membrane
The preceding experiments suggested that C-PC/β treatment inhibited cancer cell
proliferation and induced apoptosis. C-PC/β treatment activated caspase and caused cell cycle
arresting. To understand the molecular basis for the apoptotic induction and cell cycle arresting,
we examined localization of the recombinant C-PC/β in cells after the treatment. We employed
Immunofluorescent staining to detect the GST:C-PC/β in 686LN-M4C1 cells using antibody
against GST. The recombinant GST:C-PC/β was mainly stained on the cancer cell plasmamembrane (Figure 13). While the membrane staining pattern was not observed with non-cancer
cells. Interestingly, the level of accumulation of membrane C-PC/β correlated with the degree of
cell proliferation inhibition (Compare Figure 13 to Figure 8). This observation suggested a
potential role of plasma-membrane C-PC/β in cell proliferation inhibition.
Tubulin and GAPDH were the target proteins on the plasma membrane
Since the recombinant C-PC/β proteins were mainly accumulated on the cancer cell
membrane, we attempted to probe the protein or protein complex that interacted with C-PC/β in
the plasma membrane. To this end, a GST-pull down experiment with membrane extracts made
from 686LN-M4C1 cells using the GST:C-PC/β was carried out. A 55 kDa and a 36 kDa protein
bands were among the other proteins that specifically associated with the GST:C-PC/β were
found (Figure 14). The protein bands were excised out. After the in-gel trypsin digestion,
MALDI-(ms/ms) analyses (Figure 15) showed that the 55 kDa band was β-tubulin (gi|57209813,
NCBI) and the 36 kDa band was Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
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(gi|31654, NCBI). The identity of the proteins was further verified by immunoblot (Figure 16).
In addition, the interactions of C-PC/β with β-tubulin and GAPDH were further confirmed by
co-immunoprecipitation experiments carried out using antibodies against β-tubulin and GAPDH
with the cell extracts made from C-PC/β treated 686LN-M4C1 cells.
C-PC/β interacted with β-tubulin on the cell membrane promoting depolymerization of
microtubules
Since the recombinant C-PC/β proteins were mainly accumulated on the cancer cell
membrane, we attempted to probe the protein or protein complex that interacted with C-PC/β in
the plasma membrane. We found that tubulin and GAPDH were specifically associated with
GST:C-PC/β. First, we asked whether the cytoskeleton microtubules were affected by this
interaction.
We examined ratio of depolymerized/polymerized tubulin by immunoblotting the
soluble/unsoluble tubulin in whole cell extract of the C-PC/β treated 686LN-M4C1 cells. The
ratio of depolymerized/polymerized tubulin was around 0.949 for C-PC/β treated cells, and was
0.371 for PBS treated cells (Figure 17). This data suggests that there was a substantially higher
level of soluble tubulin in C-PC/β treated cells compared to untreated cells. This was an
indication that microtubules were depolymerized under the treatment of the β subunit of C-PC.
Interestingly, we found that microfilaments were also depolymerized under the treatment of the
C-PC/β by similar experimental approaches. The ratio of depolymerized/polymerized actin was
around 0.721 for the C-PC/β protein treated cells and was 0.211 for PBS treated cells (Figure 17).
Thus, our results demonstrated that C-PC/β interacts with β-tubulin on the cell membrane
promoting depolymerization of cytoskeletons, and both microtubules and microfilaments.
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C-PC/β interacted with GAPDH and promoted GAPDH nuclear translocation
Interaction of C-PC/β with GAPDH is intriguing. Biological functions of GAPDH were
dependent upon the subcellular localization. The nuclear form of GAPDH has been suggested to
be a key transcriptional coactivator necessary for entry into S phase [Zheng, 2003; Sirover,2005]
We have observed the effects of C-PC/β on cell cycle progression. The cells were arrested in the
G0/G1 phase under the treatment of the C-PC/β. We suspected that C-PC/β treatment may have
effects on GAPDH cellular localization. To test this idea, we examined the level of GAPDH in
the cell nucleus and cytoplasm by immunoblotting the GAPDH in the nuclear extracts and whole
cell lysate made from 686LN-M4C1 cells before and after the C-PC/β treatment. It was clear that
the level of the nuclear GAPDH was greatly decreased after the incubation with the C-PC/β for
24 hours. Interestingly, GAPDH expression level was higher under the treatment of the C-PC/β
as demonstrated via immunobloting a whole cell lysate by antibody against GAPDH (Figure 18).
This might be the result of feedback of the low level of the nuclear form of GAPDH.
No difference in distribution of β-tubulin and Histone H2A was observed under C-PC/β
treatment
Since the expression level of GAPDH was increased and the nuclear distribution was
significantly reduced under the C-PC/β treatment. We wondered whether this phenomenon was
specific to the GAPDH. To this end, we examined the nuclear level of β-tubulin and Histone H2a
by the same experimental procedure. Our results showed that, both β-tubulin and Histone H2A
did not change the expression level and cellular localization under the treatment of C-PC/β for
24 hours (Figure 19). We therefore conclude that C-PC/β treatment leads to nuclear export and
up-regulation of GAPDH. The effects on the distribution and expression of GAPDH under the
treatment of C-PC/β are likely specific.
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Graph 1 The selectivity curve for
superdex 200 prep grade
(Amershan Bioscience, data file of gel
filtration media: Superdex 30, 72 & 200
prep grade BioProcessTM Media)
A selectivity curve is usually fairly straight over the range Kav=0.1 to Kav=0.7, which is shown
in Graph 1. The molecular weight range, which lies between these values, is defined as the
useful fractionation range of the medium. Proteins with a molecular weight between 30,000–
600,000Da MW are considered to be in the high selectivity range for Superdex 200 prep grade.
The molecular weights of GST-β, GST, and β are in this range.
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Figure 1 Whole cell PCR product for β subunit of C-PC.
Lane 1 and lane 2 were the PCR products of β for vector pGEX-2T; Anabaena PCC 7120 alga
was used. 0.5 Kb DNA fragments were obtained for each product. The amplified DNA product
contains BamHI and EcoRI sites, which were used to clone into the pGEX-2T vector.
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a.
b.

Figure 2 Vectors.
(a) Map of pGEM-4Z; (b) Map of pGEX-2T. This figure shows the maps of two vectors used.
pGEX-2T was used to express the subunit of C-PC. In the pGEM-4Z vector, the Sma I
recognition site in the multiple cloning region was used to clone the PCR product; in pGEX-2T
vector, the BamH I and EcoR I recognition sites were used to sub-clone the PCR products.
pGEX-2T is an expression vector for fusion protein, which encodes glutathione S-transferase
gene at the N-terminus of the fused protein; there is also a thrombin recognition site between the
GST and the fused protein.
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Table 1 The amino acid sequences of β subunit of C-PC (Anabaena 7120) and GST (pGEX-2T).
β subunit of C-PC

GSmtldvftkvvsqadsrgeflsneqldalanvvkegnkrldvvnritsnasaiv
tnaaralfeeqpqliapggnaytnrrmaaclrdmeiilryvtyailagdasvlddrc
lnglretyqalgtpgssvavgvqkmkdaavgiandpngitkgdcsqlisevasyf
draaaavg

GST

mspilgywkikglvqptrllleyleekyeehlyerdegdkwrnkkfelglefpnlp
yyidgdvkltqsmaiiryiadkhnmlggcpkeraeismlegavldirygvsriay
skdfetlkvd klsklpemlkmfedrlchktylngdhvthpdfmlydaldvvly
mdpmcldafpklvcfkkrieaipqidkylksskyiawplqgwqatfgggdhppk
sdlvprgsrrasvgspgihrd

www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=38893 (subunits of C-PC)
www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=345178 (GST)
The published gene sequences of the subunits of C-PC were obtained from Pubmed (No.
X05239). The DNA sequence of GST was also obtained from Pubmed (No. A01438). Note: The
capital amino acids in the sequence of β/C-PC were from pGEX-2T vector.

Table 2 Theoretical analysis of the proteins.

Protein

Molecular
weight

PI

Hydropathicity

Transmembrane
helices prediction
(topology analysis)

Stability

GST
GST-β
β

28165.7
46678.6
18530.9

7.05
6.22
5.0

-0.385
-0.234
-0.025

no
no
no

stable
stable
stable

Modern transmembrane prediction and Protparam (Swiss-Prot/TrEMBL) soft analysis on the
website (http://www.expasy.org/) were used to analyze the theoretical molecular weight, PI,
hydropathicity, transmembrane helices predicted, and stability level of each protein.
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Figure 3 Expression of the recombinant GST tagged βsubunit of C-PC in E. coli BL 21.
Bacterial cell lysates were analyzed in 10% SDS-PAGE, before IPTG induction (lane 1: GST:CPC/β); after IPTG induction (lanes 2, 3: GST:C-PC/β).
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GST-β β

GST

Figure 4 Purified proteins of GST:C-PC/β, β and GST
The recombinant proteins (GST-β, β and GST) were further purified by gel filtration: Sephadex200. Purified recombinant proteins were analyzed by 10% SDS-PAGE gel. Lane 1: recombinant
GST:C-PC/β; lane 2: recombinant β; lane 3: recombinant GST
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M 1
Figure 5 Dialysis β subunit of C-PC.

2

The β subunit of C-PC was dialyzed; and a 10% SDS-PAGE gel was used to analyze the
recombinant proteins. Lane 1, the β subunit of C-PC was dialyzed in the dialysis buffer
without reducing agent added; lane 2, the β subunit of C-PC was dialyzed in the dialysis buffer
with reducing agent added.
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Figure 6 Mass spectrometry of GST and GST:C-PC/β.
Molecular weights of the obtained recombinant proteins were determined by MALDI-TOF
mass spectrometry. (a), mass spectrometry of GST, which indicated that the molecular weight
of the recombinant GST is 27.1 kDa; (b), mass spectrometry of GST:C-PC/β, which showed
that the molecular weight of the recombinant GST:C-PC/β is 45.4 kDa.

32

120
100
80
60
40
20
0
0.44µM GST-β

4.4µM GST-β

PBS

Figure 7 Proliferation of K562 cells treated with different doses of GST:C-PC/β.
MTT assays of cell proliferation of K562 cells treated with different doses of GST:C-PC/β.
The optimum dosage of the protein to the K562 cell was around 5µM. The cell proliferations
were expressed as percentage of growth and were calculated in comparison to PBS treated cells.
The number of cells in the control was taken as 100%. Values were calculated as mean ± S.D.
of triplicate measurements (P<0.05).

Figure 8 Proliferation of six cell lines under the treatment of 5µM of GST:C-PC/β.
MTT assays of cell proliferation of different cell lines (indicated) treated with different agents
(indicated). The treatment of GST was used as a control. The results suggested that 5µM of the
recombinant C-PC/β inhibits the growth of cancer cells greatly.
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Figure 9 Morphology of the cells under different treatments.
Morphologies of different cell lines (indicated) upon the treatments of 5µM of GST:C-PC/β or
other agents (indicated). GST (5µM) and PBS treatments of different cells were used as a
control.
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Figure 10 Apoptosis assay of six cell lines under different treatments.
Apoptosis of different cell lines (indicated) upon treatment with different agents (5µM of
GST:C-PC/β, 5µM of GST, and PBS ). Apoptosis was expressed as the enrichment of monoand oligonucleosomes released into the cytoplasm.

Figure 11 Immunoblot analyses of the activities of Caspase-3 and Caspase-8
Immunoblot analyses of cellular Caspase -3 and -8 in cell extracts made from 686LN-M4C1
cells that were treated with recombinant C-PC/β or PBS using antibodies against Cas-3 or Cas8. The arrows indicate the cleavage products (Cle-Cas 8, and Cle-Cas 3).
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Figure 12 Cell cycle analysis of
686LN-M4C1 after the treatment of
5µM of recombinant C-PC/β

FACS analyses of cell cycle of 686LN-M4C1 cells upon the treatment of PBS (solid line) or CPC/β (dot line). An accumulation of cells with 2N DNA contents and a decrease in cells with
4N DNA was evident by comparing to that of untreated cells. An increase in cells with a subG1 DNA content was clearly observed.
K562

686LN

C5/MJ

686LN-M4C1

HT29

RPMI 1788

Figure 13 Immunofluorescent staining of GST:C-PC/β in different cell lines upon 5µM GST:CPC/β treatment.
Immunofluorescent staining of GST:C-PC/β in different cell lines (indicated) upon 5 µM
GST:C-PC/β treatment using antibody against GST under confocal technique. The green signal
represents staining of GST:C-PC/β.
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Figure 14

GST pull down experiment and SDS-PAGE

analysis.
SDS-PAGE analysis of GST:C-PC/ β pull-down from
membrane extracts made from 686LN-M4C1 cells. The
proteins were pulled down by GST:C-PC/β(IP). The GST
moiety, the column (Col.), and the membrane extracts (ME)
were used as controls. Arrows indicate the protein bands that
associate with C-PC/β.

tubulin, beta pol...[gi:57209813] chromosome="6"
mfwevisdehgidptgtyhgdsdlqldrisvyyneatggkyvprailvdlepgtmdsvrsgpfgqifrpdnfvfgqsgagnnwakghytegae
lvdsvldvvrkeaescdclqgfqlthslgggtgsgmgtlliskireeypdrimntfsvvpspkvsdtvvepynatlsvhqlventdetycidnealydi
cfrtlklttptygdlnhlvsatmsgvttclrfpgqlnadlrklavnmvpfprlhffmpgfapltsrgsqqyraltvpeltqqvfdaknmmaacdpr
hgryltvaavfrgrmsmkevdeqmlnvqnknssyfvewipnnvktavcdipprglkmavtfignstaiqelfkriseqftamfrrkaflhwytge
gmdemefteaesnmndlvseyqqyqdataeeeedfgeeaeeea
33.8% match: 144/426

GAPDH sequence
mgkvkvgvngfgrigrlvtraafnsgkvdivaindpfidlnymvymfqydsthgkfhgtvkaengklvingnpitifqerdpskikwgdagaey
vvestgvfttmekagahlqggakrviisapsadapmfvmgvnhekydnslkiisnascttnclaplakvihdnfgiveglmttvhaitatqktvdgps
gklwrdgrgalqniipastgaakavgkvipeldgkltgmafrvptanvsvvdltcrlekpakyddikkvvkqasegplkgilgytehqvvssdfns
dthsstfdagagialndhfvkliswydnefgysnrvvdlmahmaske
25.1% match: 84/335

Figure 15 MALDI/TOF/TOF-MS analyses of the C-PC/β association proteins.
MALDI/TOF/TOF-MS analyses of the proteins, which were pulled down by GST:CPC/β. The whole amino acid sequences were obtained from NCBI. Bold characters
indicate the sequences identified by the mass-spectroscopy.
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Figure 16 Immunoblot and co-immunoblot methods to further prove the interaction between CPC/β and β-tubulin or GAPDH.
(a) Immunoblot analyses of the GST:C-PC/β pull-downs by immunoblot using antibodies
against β-tubulin (IB:β-tubulin) and against GAPDH (IB:GAPDH). (b) Co-immunoprecipitation
of GST:C-PC/β by the antibodies (IP: Ab) against β-tubulin (β-tub) and GAPDH (GAPDH) was
analyzed by immunoblot the co-precipitates using appropriate antibodies (indicated). IP by
mouse IgG was a control for the co-immunoprecipitation.
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a,

Figure 17 Soluble and assembled tubulin/ actin measurement via immunoblot method.
Immunoblot analyses of soluble (S) tubulin and actin and assembled (P, precipitates) tubulin and
actin in the soluble and insoluble extracts made from the PBS or C-PC/β treated 686LN-M4C1
cells (upper panel). The lower panel shows the quantification of the immunoblotting results
expressed as ratio of soluble/insoluble tubulin (filled bars) and actin (open bars).
b,

a,
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Figure 18 Expression level and subcellular distribution of GAPDH via immunoblot method.
a) Immunoblot analyses of cellular (lysate) and nuclear (NE) amounts of GAPDH in PBS or
C-PC/β treated 686LN-M4C1 cells. IB of β−tubulin is used as a loading control. b) The
lower panel shows the quantification of the immunoblotting results expressed in comparison
to PBS treated results. The quantifications were expressed as relative GAPDH levels in
nuclear extracts or in total cell lysate by defining the GAPDH levels in nuclear extracts or in
total cell lysate made from PBS treated cells as 1(open bars).

Figure 19 Distribution of β-tubulin and Histone H2A under C-PC/β treatment.
Immunoblot analyses of cytoplasmic (CE) and nuclear (NE) levels of β-tubulin and Histone
H2A in PBS or C-PC/β treated 686LN-M4C1 cells. No changes in distribution of β-tubulin
and Histone H2A were observed.
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DISCUSSION

A high yield of the recombinant proteins in E. coli BL-21, means subunit of C-PC are
suitably expressed in E .coli bacteria (in the text, only beta subunit of C-PC was shown). This
will help us study the characteristics of the subunits of C-PC. Both blue-green algae and E.
coli belong to Eubacteria (same codon bias). They may share the similar protein modification
systems. The recombinant protein should be modified the same way as the native protein.
This study suggests that E. coli can be used to express and analysis other proteins from bluegreen algae.
The molecular weight difference between theoretical molecular weight and MS
analysis results may be caused by the purified protein not forming the disulphate bridge. The
refolded protein sample treated with loading buffer without reducing reagent shows two
bands (Figure 5, lane 1). It suggests that the bold band is the linear protein, which might be
oxidized by the SDS contained in the gel, while the faint band still contains the disulphate
bridge. The refolded protein sample treated with loading buffer (contained reduced reagent)
(Figure 5, lane 2) ran as fast as the bold band (Figure 5, lane1). It is quite possible that the
disulphate bridge of the protein, under the treatment of both reducing reagent and SDS, was
totally oxidized. Therefore, only one band was observed (Figure 5, lane 2). It is not known
whether the formation of the disulphate bridge will affect the pharmacological characteristics
of the β proteins.

Based on the proliferation assays, C-PC/β has a higher inhibitory effect on highly
metastatic cancer cells (686LN-M4C1 and K562) than on other cancer cells can be concluded.
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GST had no significant proliferation inhibitory effect on all the cell lines under the treatment,
which means the functional domain of the fusion protein is C-PC/β. Importantly, C-PC/β
showed much lower proliferation inhibition effect on non-cancer cells than on cancer cells.
Though all the cancer cell lines showed cell proliferation inhibition under the
treatment of recombinant C-PC/β, the apoptosis level of different cells does not correlate to
the proliferation inhibition level. HT29 cells showed almost no apoptosis. As shown in the
morphological characteristic (discussed in the last chapter), no obvious HT29 cell necrosis
had occurred under the treatment. C-PC/β might induce growth stress on HT29, which
slowed down the growth rate of the cells. No apoptotic phenomenon was observed among
non-cancer cells. C-PC/β might slow down the growth rate of the non-cancer cells as well.
Both Caspase-8 and Caspase-3 were observed to be activated under the treatment of
C-PC/β. While the pull-down results showed that cell death receptor may not directly
targeted by the recombinant proteins. However, the target proteins (as indicated in the latter
experiments) may recruit adaptor protein(s) on the cytoplasmic side. The adaptor protein, in
turn, recruits Caspase-8 to trigger the death-inducing signal pathway. Caspase-8 will then be
activated and is now able to directly activate Caspase-3, an effector protein, to initiate
degradation of the cell.
It is intriguing that C-PC/β treatment activates Caspase-3 and -8, which subsequently
triggers cell apoptosis. It was reported that the biliprotein C-PC purified from blue-green
algae also induces cell apoptosis [Pardhasaradhi, 2003; Reddy, 2003; Subhashini, 2004].
However, the mechanism by which the C-PC triggers apoptosis seems different from the
mechanism by which C-PC/β induces apoptosis. The C-PC enters the cytoplasm of cancer
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cells [Subhashini, 2004], while the recombinant C-PC/β was mainly accumulated on the
plasma membrane of K562 cells. On the other hand, under the same treatment of C-PC or CPC/β, different cell lines show different responses. This phenomenon was reflected in
previous studies, in which C-PC was used as the treatment agent. Activation of Caspase-8
was detected in Hela cells [Li, 2005], while not in K562 cells [Subhashini, 2004]. Activation
of Caspase-8 was observed under C-PC/β treatment in our experiment. Different cell lines
showed different treatment responses were also observed in this study. Under the C-PC/β
treatment, cytoplasm GAPDH might be associated with actin and trigger the
depolymerization of the actin. There is no evidence to demonstrate that C-PC has any effect
on cytoplasm or nuclear GAPDH. This study suggests that the recombinant β subunit of CPC works more effectively in inhibition of cell proliferation and apoptosis induction than the
purified C-PC does.
686LN-M4C1 cells were mainly in the G0/G1 phase after the cells were treated with
the C-PC/β. C-PC/β may interact with specific protein(s) that affect DNA replication and
block the cell from moving into S-phase. The important question is where does C-PC/β
interact with the cells. Another question is that, which protein(s) was (were) the interactive
target for C-PC/β.
C-PC/β was mainly accumulated on the cell plasma membrane, which is consistent
with the predicted property of C-PC/β proteins (no transmembrane domain was predicted).
On the other hand, C-PC/β has low accumulation level on non-cancer cell surfaces. This may
due to the membrane proteins have different structures/protein complexes between cancer
cells and non-cancer cells.
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One question is that whether the extract detergent disrupted the interaction between
GAPDH/tubulin and the cell death receptor. On the other hand, the trace amount of proteins
in the loading sample was not visible in SDS-PAGE gel. Therefore, GAPDH and tubulin
might not be the only proteins associated with C-PC/β. Promisingly, both GAPDH and
tubulin play an important role in the toxic effects on the cancer cells.
The main disadvantage of traditional IP and Co-IP is that the conditions used to elute
the precipitated antigen also released the antibody, contaminating the antigen and destroying
the antibody support. This phenomenon was reflected in our Co-IP results:β-tubulin has a
similar molecular weight as the heavy chain, which caused the immunoblot result of βtubulin to be quite faint (Figure 16 b).
Tubulin and GAPDH were the associated proteins for C-PC/β on the plasma
membrane. Therefore, we focused on these two proteins and tried to find the mechanism how
they play a role in apoptosis.
GAPDH functions as a glycolytic enzyme within the cytoplasm, but beside its
metabolic function it is involved in early steps of apoptosis, which trigger the translocation of
GAPDH into the nucleus [Dastoor, 2001]. Interestingly, our results showed that, under
treatment with C-PC/β, a greater amount of GAPDH was in the cytoplasm, and subsequently
led to the apoptosis. A previous report showed that GAPDH expression is three times greater
in apoptotic cells compared to non-apoptotic ones. The results also showed that GAPDH was
over expressed during the treatment with C-PC/β. Both over-expression and abnormal
distribution of the GAPDH inside of the cell might be the main reasons for the programmed
cell death. C-PC/β cause 686LN-M4C1 cells to arrest at G0/G1 phase of cell cycle. The data
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showed that C-PC/β treatment led to a great amount of GAPDH localization inside the
cytoplasm. It is conceivable that low levels of nuclear GAPDH induced by C-PC/β treatment
cause the cell cycle arrest, which subsequently inhibited cell proliferation. How the C-PC/β
reduces nuclear GAPDH level is an open question. The speculation is, during treatment with
the C-PC/β proteins, GAPDH is targeted by C-PC/β and recruited to the plasma membrane.
This recruitment promotes nuclear export of GAPDH. It has been shown that if the amount of
GAPDH in the nucleus is lowered to a certain level, it then inhibits the cells’ ability to enter
into S phase [Zheng, 2003]. Lower levels of nuclear GAPDH will in turn activate the
expression of GAPDH.
The roles of actin and tubulin in tumor cell blebbing (apoptosis) have been reported
[Ostrowski, 2005; Vilpo, 2000]. This study showed that both actin filaments and
microtubules were depolymerized under the treatment of C-PC/β. Also, 686LN-M4C1 cells
were induced into apoptosis. It is believable that the C-PC/β inhibits cell proliferation and
promotes apoptosis by triggering cytoskeleton depolymerization and activation of Caspases
that are associated with the extrinsic apoptosis pathway. Actin filaments were also reported to
be associated with GAPDH under stressful environments [Schmitz, 2002]. The
depolymerization of actin might result from the association with GAPDH under the apoptotic
induction by C-PC/β. Depolymerization of actin might also be the result of the apoptosis.
The tubulin was depolymerized during the treatment of C-PC/β, while there was no
significant change of expression and cellular distribution of tubulin. It is might be concluded
that the proliferation and apoptosis of 686LN-M4C1 only related to the polymerization status
of the tubulin. Histone H2A showed no distribution inside the cytoplasm: this showed that
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cytoplamic protein solution had not been contaminated by the nuclear protein. With twentyfour hours of treatment with C-PC/β, almost no degraded DNA was released into the
cytoplasm and no Histone H2A was observed inside the cytoplasm.
Tubulin is one of the intracellular molecular targets of many anticancer drugs, such as
Colchicine (C9754, Sigma), Nocodazole (M1404, Sigma), and Paclitaxel (T7191, Sigma).
Tubulin-binding agents that cause rapid depolymerization of cytoskeletal microtubules show
promise as cancer targeting agents. GAPDH has been implicated in certain neurological
diseases: GAPDH is able to bind to the gene products from neurodegenerative disorders such
as Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, and Machado-Joseph
disease through stretches encoded by their CAG repeats. The interaction of GAPDH with
disease-related proteins suggests that it is a potential molecular target for drug development
[Chuang, 2005]. Both tubulin and GAPDH associated on the cell plasma membrane were the
targets for the C-PC/β. C-PC/β is a good binding agent for both tubulin and GAPDH.
Previous results showed that C-PC entered K562 cells under incubation with C-PC; however,
the β subunit of C-PC was not easily released from the whole C-PC [Duerring, 1991].
Whether this anti-cancer property is more effective if C-PC/β is delivered inside of the cancer
cell is not known. Therefore, it will be a good idea to introduce the C-PC/β into the
cytoplasm to test the anti-cancer effects.
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APPENDICS
Chemicals
acrylamide/bisacrylamide solutions: Fisher BioReagent
acetonitrile (CAN): VWR International
acetic acid: VWR International
AEBSF(4-(2-Aminoethyl)benzenesulphonyl fluoride): Calbiochem
agarose: MP Biomedicals
ammonium persulfate (APS): Sigma Aldrich
ampicillin solutions: Teknova
Bio-Rad protein assay: Biorad Laboratories
boric acid: Biorad Laboratories
bovine serum albumin (BSA): Promega
bromophenol blue: EMD Biosciences
β-mercaptoethanol: Sigma Aldrich
CaCl2: Sigma Aldrich
citric acid: Fluka
Coomassie Blue: Sigma Aldrich
cyanogen bromide: Sigma Aldrich
DAPI (4’,6’-diamidino-2-phenylindole): Sigma Aldrich
DMSO (dimethyl sulphoxide): Pierce
DTT (dithiothreitol): Shelton Scientific
DMEM (Dulbecco’s Modified Eagle’s Medium): HyClone
dNTP mixture: Takara Mirus Bio
EGTA (ethylene glycol bis-N,N,N’,N’-tetraacetic acid): Sigma Aldrich
ethanol: AAPER Alcohol & Chemical
EB (ethidium bromide): Sigma Aldrich
EDTA (ethylenediaminetetra-acetic acid): Sigma Aldrich
formic acid: EMD Biosciences
FCS (fetal calf serum): HyClone
formaldehyde: Calbiochem
gelcode® blue stain reagent: Pierce
glutathione: Sigma Aldrich
glutathione-agarose: Sigma Aldrich
glycerol: Sigma Aldrich
glycine: MP Biomedicals
isopropanol: VWR International
IPTG (isopropyl-beta-D-thiogalactopyranoside): Sigma Aldrich
image-iTTM FX signal enhancer: Molecular Probes
lysozyme: Sigma Aldrich
KCl: Fisher Bioreagent
KH2PO4: Fisher Bioreagent
MgCl2: Fisher Bioreagent
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methanol: VWR International
NaCl: Fisher Bioreagent
NaHCO3: Fisher Bioreagent
Na2HPO3: Fisher Bioreagent
NaH2PO3: Fisher Bioreagent
TEMED (N,N,N’,N’-tetramethylethylene diamine): Sigma Aldrich
NaOH: Fisher Bioreagent
NP-40: Roche Applied Science
N-Lauroyl sarcosine (C15H28NO3Na): Sigma Aldrich
oxidized glutathione: Sigma Aldrich
paclitaxel: Sigma Aldrich
paraformaldehyde: Sigma Aldrich
penicillin: Mediatech
PFU and PFU buffer: Sigma Aldrich
phenol/chloroform: Promega
PMSF (phenylmethylsulfonyl fluide): Fluka
PI (propidium iodide) /RNase staining buffer: BD Bioscience
protease inhibitor cocktail: Sigma Aldrich
RPMI 1640 medium: HyClone
reduced glutathione: Sigma Aldrich
RIPA buffer: Sigma Aldrich
SDS (sodium dodecylsulfate): Fisher BioReagent
streptmycin: Mediatech
thrombin: Sigma Aldrich
trypsin-EDTA: Cellgro
tryptone: Sigma Aldrich
syringe filter (0.45 µm): Sigma Aldrich
Tris (tris-(hydroxymethyl)-aminomethane): Sigma Aldrich
Triton X-100: Sigma Aldrich
Tween-20: Sigma Aldrich
urea: Fisher Biotech
yeast extract: Sigma Aldrich
Enzymes and Antibodies
Sma I: Fermentas
BamH I: Fermentas
EcoR I: Fermentas
T4 Polynucleotide Kinase: Promega
T4 DNA ligase: Fermentas
Actin monoclonal Ab: SC-8432 Santa cruz biotechnology
β-tubulin monoclonal Ab: Sigma Aldrich
β-tubulin polyclonal Ab: abcam
GAPDH monoclonal Ab: Chemicon
GAPDH polyclonal Ab: abcam
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GST monoclonal Ab: Amersham Biosciences
Histone polyclonal Ab against Histone H2A: Cell Signaling
mouse monoclonal Ab of anti-caspase-3: Cell Signaling
mouse monoclonal Ab of anti-caspase-8: Cell Signaling
rabbit monoclonal Ab of anti-cleaved-caspase-3: Cell Signaling
Plasmids and cell lines
pGEM-4Z: Promega
pGEX-2T: Pharmacia
Anabaena PCC 7120: UTEX
E. coli BL-21: Stratagene
JM 109: Promega
C5/MJ: T lymphocyte (ATCC)
HT 29: colorectal adenocarcinoma (ATCC)
K562: Human chronic myeloid leukemia cells (ATCC)
686LN: 686LN was derived from a squamous cell carcinoma of the head and neck patient’s
metastatic tumor (a gift from George Z. Chen in Amory University)
686LN-M4C1: 686LN-M4C1 was derived from 686LN cells passaged four times in nude
mice (a gift from George Z. Chen in Amory University)
RPMI 1788 cells: B lymphocyte (ATCC)
Laboratory equipments
AKTA Basic 10 FPLC System: Amershan Bioscience
AllegraTM 6R Centrifuge: Beckman Coulter
C25 Indubator Shaker: NewBrunswick Scientific
FACS (Becton Dickinson): GE Healthcare
EasyCastTM Horizontal Electrophoresis System: Owl Separation System
EasyCastTM Vertical Electrophoresis System: Owl Separation System
EpiChemi3TM Darkroom Bioimaging System: UVP, Inc.
Eppendorf Centrifuge 5415D: Eppendorf AG
Eppendorf Mastercycler: Eppendorf AG
Gel Dryer: Fisherscientific
Mini-PROTEAN@ll Eletrophoresis Cell: Biorad Laboratories
Mini Trans-Blot Cell: Biorad Laboratories
NanoPure DiamondTM Water System: Barnstead International
NuAireTM CO2 Water-Jacketed Incubator: NuAire
Phosphoimager BAS 1500: FUJIFILM Medical Systems
Precision Durafuge 100: Precision
RC-5C PLUS Superspeed Refrigerated Centrifuge: Thermo Electron Corporation
Rotomix Variable Speed Rotator: Barnstead International
Sonic Dismembrator 500: Fisherscientific
UV-1700 UV-Visible Spectrophotometer: Shimadzu Corporation
Vacufuge Concentrator 5301: Eppendorf AG
Victor3V 1420 Multilabel Counter: Perkin Elmer
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VistaVision Microscope: VWR International
Reagents, Kits and other materials:
Alexa Fluor 488 goat anti-mouse IgG (H+L): Molecular Probes
Immunopure Protein A agarose: Molecular Probes
Prolong Gold anti-fade reagent: Molecular Probes
Cell Death Detection ELISAPLUS Kit: Roche
CellTiter 96® non-Radioactive Cell Proliferation Assay: Promega
Image-iTTM FX Kit: Molecular Probes
Mem-PER® Eukaryotic Membrane Protein Extraction Reagent Kit: Pierce
Nuclear extraction Kit: Active Motif
ProteoProfileTM Trypsin In-Gel Digest Kit: Sigma Aldrich
ProteoSilverTM Plus Silver Stainin Kit: Sigma Aldrich
QIAquick PCR Purification Kits: QIAGEN
QIAprep® Spin Miniprep Kits: QIAGEN
QIAquick Gel Extraction Kit: QIAGEN
Rapid DNA Ligation Kit: Fermentas
Centriprep Centrifugal Filter Devices: Amicon
culturewellTM chambered cover-glass: Molecular Probes
multichannel pipette: Eppendorf
nitrocellulose: Optitran BA-S83, Schleider & Schuell
Sephedex 200 gel-filtration column: Amershan Bioscience
Siliconized Eppendorf tube: Sigma Aldrich
sterile 96-well cell culture plates: Promega
syringe filter (0.22 µm): Sigma Aldrich
Paraffin-wax-coated matrix-assisted laser desorption/ionization (MALDI) target plate: Ion
Channel Media Group
ZipTip C18 tips: Millipore
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